Phase 2Completed

Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis

Multicenter, Double Blind, Metronidazole Controlled, Dose Range Finding Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis

Sponsor
Romark Laboratories L.C. (Industry)
Enrollment
114 planned
Conditions
Clostridium Difficile
Interventions
Nitazoxanide; Metronidazole
Ages
adults, older adults
Registry
NCT00417872

Full record on ClinicalTrials.gov

From the registry

The primary objective is to demonstrate non-inferiority of nitazoxanide administered 500 mg b.i.d compared to metronidazole administered 250 mg q.i.d. in resolving symptoms of Clotridium difficile colitis after seven days of treatment. Secondary objectives are to provide information on the times from first dose to last unformed stool and resolution of symptoms of colitis, the sustained response rates for the different tratment groups and the effect of treatment on Clostridium difficile toxin enzyme immunoassay/culture results during hospitalization.

Primary outcomes

  • Clinical response (resolution of all symptoms present at baseline) recorded on day 8

History

  1. Registered

  2. Study completion

  3. Started